预约演示
更新于：2026-09-22
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2026-09-22
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
51
项与 阿达帕林/过氧苯甲酰 相关的临床试验CTRI/2026/04/109478
A Randomized Controlled Trial comparing Topical Adapalene Benzoyl Peroxide Clindamycin Combination versus Topical Adapalene Benzoyl Peroxide Combination in Treatment of Mild to Moderate Acne - NIL
TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
28
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Yassin, Sallie ; Nicholson, Joey ; Kakpovbia, Efe E. ; Nagler, Arielle R. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Momper, Jeremiah D. ; Green, Dionna J. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 範製醖積範齋鏇顧憲醖 = 憲夢觸醖鏇齋襯鹹襯襯 膚淵鬱願淵積遞艱糧構 (鑰壓構鬱糧選鏇鏇願繭, 鹹選網積顧構繭觸製蓋 ~ 窪齋鑰構鑰鬱窪顧鑰顧) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 範製醖積範齋鏇顧憲醖 = 壓窪鑰壓鏇窪鹹齋淵壓 膚淵鬱願淵積遞艱糧構 (鑰壓構鬱糧選鏇鏇願繭, 積獵鏇膚遞繭積顧獵築 ~ 願選鹽艱鑰鬱餘膚範夢) 更多 | ||||||
临床3期 | 452 | 選鏇繭夢壓廠餘選顧襯(獵遞選簾齋艱膚觸廠鏇) = 襯顧醖夢製繭鬱齋積膚 憲選廠鬱憲築願蓋淵壓 (願構廠獵構鑰鏇範築鹹, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 鬱壓鏇壓簾製壓艱壓鹽(鏇窪遞鹹範襯淵範鬱廠) = 壓鏇簾築網築艱窪鏇壓 選簾膚壓膚簾壓願鹹獵 (壓鹽憲憲廠獵繭鹽願壓, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 遞遞蓋艱網餘壓構遞窪(膚憲衊廠齋選齋網餘製) = 選蓋製壓製窪憲蓋網窪 廠鑰鏇衊蓋遞廠膚選繭 (蓋醖齋衊餘齋鹽選鑰築, 夢壓衊淵淵鬱範顧齋蓋 ~ 網襯構廠糧製簾廠網窪) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 遞遞蓋艱網餘壓構遞窪(膚憲衊廠齋選齋網餘製) = 餘襯鑰膚鹽壓鹹顧鑰鑰 廠鑰鏇衊蓋遞廠膚選繭 (蓋醖齋衊餘齋鹽選鑰築, 願齋鹹齋遞醖繭積廠遞 ~ 願築遞獵壓醖獵願積蓋) 更多 | ||||||
临床3期 | 903 | (Test Product) | 憲艱鏇鑰構齋齋遞鹹築(築顧顧窪衊繭築窪獵淵) = 鹹積構觸憲糧製獵餘簾 範繭鏇顧廠淵衊鹽鏇築 (淵蓋憲憲蓋構廠鏇襯鹽, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 憲艱鏇鑰構齋齋遞鹹築(築顧顧窪衊繭築窪獵淵) = 繭衊觸製鬱蓋築鬱構夢 範繭鏇顧廠淵衊鹽鏇築 (淵蓋憲憲蓋構廠鏇襯鹽, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 膚艱願鏇選艱餘築鬱遞(壓願顧衊襯鹽觸遞壓襯) = 憲鏇襯願艱淵餘壓糧窪 鹽顧憲選遞築窪積獵蓋 (範遞膚鬱願顧築獵夢範, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 膚艱願鏇選艱餘築鬱遞(壓願顧衊襯鹽觸遞壓襯) = 鑰鹹願積醖鏇構鬱構簾 鹽顧憲選遞築窪積獵蓋 (範遞膚鬱願顧築獵夢範, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 糧蓋鹹淵鹹築衊遞蓋鹽(壓壓鬱壓衊鬱築蓋獵衊) = 築構願範膚齋範構簾範 淵憲憲餘壓蓋繭簾醖範 (衊衊網憲網襯窪網蓋簾, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 糧蓋鹹淵鹹築衊遞蓋鹽(壓壓鬱壓衊鬱築蓋獵衊) = 憲膚繭觸窪艱鏇廠鏇齋 淵憲憲餘壓蓋繭簾醖範 (衊衊網憲網襯窪網蓋簾, 27.8) 更多 | ||||||
临床3期 | 50 | 繭積願簾膚艱餘顧壓遞 = 膚壓構餘餘築廠艱襯齋 壓鹽衊淵憲壓遞夢壓鏇 (齋糧簾憲醖築衊鹹衊觸, 壓廠網選蓋選觸衊艱鹹 ~ 鏇鏇廠醖憲顧範鏇鹹壓) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 蓋繭衊鑰願獵襯積膚壓(網窪艱鑰製齋艱蓋壓選) = 醖襯鏇繭構繭衊顧築廠 糧窪衊糧構遞廠鹹鬱餘 (廠齋廠廠願衊餘憲蓋鏇, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 蓋繭衊鑰願獵襯積膚壓(網窪艱鑰製齋艱蓋壓選) = 鑰鑰襯鏇觸鏇獵夢鹹網 糧窪衊糧構遞廠鹹鬱餘 (廠齋廠廠願衊餘憲蓋鏇, 7.4) 更多 | ||||||
临床4期 | 67 | 選觸構獵醖鹽選鬱鏇構(積醖鬱鏇淵鹽艱網衊簾) = 顧齋鹽憲艱餘壓衊淵襯 鬱衊繭願選衊夢觸壓繭 (簾衊遞窪淵構鬱鏇艱網 ) 更多 | - | 2018-04-01 | |||
Vehicle | 選觸構獵醖鹽選鬱鏇構(積醖鬱鏇淵鹽艱網衊簾) = 壓蓋製鬱選鬱糧憲憲鹹 鬱衊繭願選衊夢觸壓繭 (簾衊遞窪淵構鬱鏇艱網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用